-
公开(公告)号：EP4242228A1
公开(公告)日：2023-09-13
申请号：EP22382228.9
申请日：2022-03-09
发明人： FERNÁNDEZ HERRERO, Luis Ángel , CASASNOVAS SUELVES, José María , MARGOLLES AZPIAZU, Yago , NORIEGA FEBRERO, María de los Ángeles , GASTAMINZA LANDART, Pablo , GARAIGORTA DE DIOS, Urtzi , MARTÍN ACEBES, Miguel Ángel , SAIZ CALAHORRA, Juan Carlos , CORBERA SÁNCHEZ, Juan Alberto
摘要： The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.
-
公开(公告)号：EP4242226A1
公开(公告)日：2023-09-13
申请号：EP22382223.0
申请日：2022-03-09
发明人： FERNÁNDEZ HERRERO, Luis Ángel , CASASNOVAS SUELVES, José María , MARGOLLES AZPIAZU, Yago , NORIEGA FEBRERO, María de los Ángeles , GASTAMINZA LANDART, Pablo , GARAIGORTA DE DIOS, Urtzi , MARTÍN ACEBES, Miguel Ángel , SAIZ CALAHORRA, Juan Carlos , CORBERA SÁNCHEZ, Juan Alberto
摘要： The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.
-
公开(公告)号：EP4242225A1
公开(公告)日：2023-09-13
申请号：EP22382222.2
申请日：2022-03-09
发明人： FERNÁNDEZ HERRERO, Luis Ángel , CASASNOVAS SUELVES, José María , MARGOLLES AZPIAZU, Yago , NORIEGA FEBRERO, María de los Ángeles , GASTAMINZA LANDART, Pablo , GARAIGORTA DE DIOS, Urtzi , MARTÍN ACEBES, Miguel Ángel , SAIZ CALAHORRA, Juan Carlos , CORBERA SÁNCHEZ, Juan Alberto
摘要： The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.
-
公开(公告)号：EP4242227A1
公开(公告)日：2023-09-13
申请号：EP22382225.5
申请日：2022-03-09
发明人： FERNÁNDEZ HERRERO, Luis Ángel , CASASNOVAS SUELVES, José María , MARGOLLES AZPIAZU, Yago , NORIEGA FEBRERO, María de los Ángeles , GASTAMINZA LANDART, Pablo , GARAIGORTA DE DIOS, Urtzi , MARTÍN ACEBES, Miguel Ángel , SAIZ CALAHORRA, Juan Carlos , CORBERA SÁNCHEZ, Juan Alberto
IPC分类号： C07K16/10 , A61K39/395 , A61P31/14 , C12N15/13 , G01N33/569 , G01N33/577
摘要： The invention relates to a nanobody directed against the receptor binding domain (RBD) of spike protein from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to a fusion protein comprising said nanobody, and to a heavy chain antibody comprising two heavy chains, wherein each heavy chain comprises said fusion protein. The invention also relates to a bivalent construction comprising two nanobodies, wherein said two nanobodies are linked by a peptide bond. The invention also relates to a nucleic acid encoding the said nanobody, fusion protein or bivalent construction, to a vector comprising said nucleic acid, to a host cell comprising said nucleic acid or said vector, and to a pharmaceutical composition comprising said nanobody, fusion protein, heavy chain antibody or bivalent construction. The invention also relates to the medical uses of said nanobody, fusion protein, heavy chain antibody, bivalent construction or pharmaceutical composition for use in the treatment and/or prevention of an infection caused by SARS-CoV-2, and to a method for diagnosing an infection SARS-CoV-2 in a subject comprising contacting a sample from the subject with said nanobody, fusion protein, heavy chain antibody or bivalent construction.
-
-
-
搜索结果
4 条记录 (耗时 0.014 秒)
